Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2015-10-02 Share Issue/Capital Cha…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Share capital increase 25 September 2015_NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated October 2, 2015, announcing that Galapagos NV raised €1.2 million through the exercise of warrants by its management committee members. It details the issuance of new shares, the resulting increase in share capital, and the total number of voting rights and outstanding warrants. This content directly relates to changes in the company's capital structure and financing activities, specifically through the issuance of shares following warrant exercises. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific capital event.
2015-10-02 Dutch
Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis
Regulatory Filings Classification · 95% confidence The document is a press release dated September 25, 2015, announcing a significant corporate and clinical development: Galapagos regaining full rights to filgotinib and advancing it to Phase 3 for rheumatoid arthritis. It also mentions the termination of an agreement with AbbVie regarding the drug and schedules a conference call. This type of announcement, detailing strategic business decisions, clinical trial progression, and partnership changes, is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on key operational and clinical milestones rather than a comprehensive review of past financial performance (like a 10-K or IR), and it is an initial announcement of results/plans, 'ER' (Earnings Release) is the most appropriate fit among the options, as these releases often contain operational highlights alongside financial summaries, or in this case, major strategic news that drives investor interest. It is not a full transcript (CT), a formal annual report (10-K), or a specific regulatory filing like DIRS or DIV. Given the focus on advancing a drug and regaining rights, it functions as a major corporate update often bundled with earnings announcements.
2015-09-28 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of September 2015. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive reports. The length is short (1248 characters), and it primarily serves as a regulatory filing to disclose information to the SEC and investors. According to the classification rules, such filings that do not fit into other specific categories and are regulatory disclosures should be classified as Regulatory Filings (RNS).
2015-09-28 English
Galapagos plant start fase 3 van filgotinib in reuma
Earnings Release Classification · 95% confidence The document is a press release dated September 25, 2015, written in Dutch, announcing clinical trial updates (start of Phase 3 for filgotinib in rheumatoid arthritis) and a change in partnership status (AbbVie terminating the agreement). It includes key financial/clinical highlights, data tables (ACR scores), and details about an upcoming conference call. This format—a formal, timely announcement of significant business/clinical developments, often preceding a full regulatory filing or earnings report—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on key results and immediate business updates rather than being a comprehensive quarterly report (IR) or a formal proxy/annual report, and it is clearly an announcement of news, 'ER' (Earnings Release) is the most appropriate fit, as these often contain clinical trial updates for biotech firms, even if not strictly tied to quarterly financials. It is not a short announcement linking to a report, so RPA/RNS is less likely than ER for this level of detail. Q3 2015
2015-09-25 Dutch
Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV, dated September 22, 2015, announcing positive Phase 1 results for their drug candidate GLPG1690, which were presented at the European Respiratory Society (ERS) congress. It details scientific findings, mentions upcoming protocol submissions for Phase 2 studies, and includes standard corporate boilerplate, contact information, and forward-looking statements. This format—a news announcement detailing recent scientific/clinical progress and corporate updates, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on presenting new clinical data and future study plans rather than summarizing overall financial performance for a period (like an ER or IR), and it is not a transcript (CT), a formal presentation (IP), or a regulatory filing announcement (RPA/RNS), it best fits the category for initial announcements of key operational/clinical progress. Given the context of presenting new data, 'Earnings Release' (ER) is often used broadly for significant operational announcements, but 'Investor Presentation' (IP) or 'Regulatory Filings' (RNS) are closer if it were the presentation itself. However, this is a press release *about* the presentation. Since it is a formal announcement of key operational/clinical news, and not a short notice about a report publication, it aligns most closely with the function of an Earnings Release (ER) in conveying timely, material information to investors, even if the primary content is clinical data rather than financial figures. Alternatively, it could be classified as RNS if no other category fits well, but ER captures the 'material announcement' nature better than RNS.
2015-09-22 English
Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERS
Earnings Release Classification · 95% confidence The document is a press release dated September 22, 2015, announcing the presentation of pre-clinical and Phase 1 results for a drug candidate (GLPG1690) at the European Respiratory Society (ERS) Annual Meeting. It details safety, pharmacokinetics, and biomarker data from the Phase 1 trial and outlines plans for a future Phase 2 study. This content structure—announcing scientific data presentation and providing key highlights—is characteristic of an Earnings Release (ER) or a general scientific update, but given the focus on presenting new clinical/pre-clinical data at a conference, it strongly aligns with the purpose of an Earnings Release (ER) which often includes key operational and scientific milestones alongside financial highlights (though financials are absent here, the structure is typical of an ER press release). It is not a full Annual Report (10-K), a formal Audit Report (AR), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI). Since it is an initial announcement of results/data presentation, ER is the most appropriate fit among the provided options, as it serves as the primary communication vehicle for period-end or milestone-based results. Q3 2015
2015-09-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.